Mice Model Generation Market (Technology: CRISPR Knockout, CRISPR Knockin, Random Insertions, Large & Targeted Insertions, ES Cell Modification, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
Mice Model Generation Market – Scope of Report
TMR’s report on the global mice model generation market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global mice model generation market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global mice model generation market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the mice model generation market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global mice model generation market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global mice model generation market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global mice model generation market.
The report delves into the competitive landscape of the global mice model generation market. Key players operating in the global mice model generation market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global mice model generation market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market mice model generation.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
- 1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Mice Model Generation Market
- 4. Market Overview
- 4.1. Introduction
- 4.1.1. Segment Definition
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Mice Model Generation Market Analysis and Forecast, 2017–2031
- 4.4.1. Market Revenue Projections (US$ Mn)
- 5. Key Insights
- 5.1. Global Genetically Engineered Mouse Model Overview
- 5.2. Regulatory Scenario by Region/globally
- 5.3. Technological Advancements
- 5.4. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
- 5.5. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
- 6. Global Mice Model Generation Market Analysis and Forecast, by Technology
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Technology, 2017–2031
- 6.3.1. CRISPR Knockout
- 6.3.2. CRISPR Knockin
- 6.3.3. Random Insertions
- 6.3.4. Large, Targeted Insertions
- 6.3.5. ES Cell Modification (homologous recombination)
- 6.3.6. Others
- 6.4. Market Attractiveness Analysis, by Technology
- 7. Global Mice Model Generation Market Analysis and Forecast, by End-user
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by End-user, 2017–2031
- 7.3.1. Pharmaceutical Companies
- 7.3.2. Biotechnology Companies
- 7.3.3. Academic & Research Facilities
- 7.3.4. Contract Research & Manufacturing Organizations
- 7.4. Market Attractiveness Analysis, by End-user
- 8. Global Mice Model Generation Market Analysis and Forecast, by Region
- 8.1. Key Findings
- 8.2. Market Value Forecast, by Region
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
- 8.3. Market Attractiveness Analysis, by Region
- 9. North America Mice Model Generation Market Analysis and Forecast
- 9.1. Introduction
- 9.1.1. Key Findings
- 9.2. Market Value Forecast, by Technology, 2017–2031
- 9.2.1. CRISPR Knockout
- 9.2.2. CRISPR Knockin
- 9.2.3. Random Insertions
- 9.2.4. Large, Targeted Insertions
- 9.2.5. ES Cell Modification (homologous recombination)
- 9.2.6. Others
- 9.3. Market Value Forecast, by End-user, 2017–2031
- 9.3.1. Pharmaceutical Companies
- 9.3.2. Biotechnology Companies
- 9.3.3. Academic & Research Facilities
- 9.3.4. Contract Research & Manufacturing Organizations
- 9.4. Market Value Forecast, by End-user by Technology, 2017–2031
- 9.4.1. Pharmaceutical Companies
- 9.4.1.1. CRISPR Knockout
- 9.4.1.2. CRISPR Knockin
- 9.4.1.3. Random Insertions
- 9.4.1.4. Large, Targeted Insertions
- 9.4.1.5. ES Cell Modification (homologous recombination)
- 9.4.1.6. Others
- 9.4.2. Biotechnology Companies
- 9.4.2.1. CRISPR Knockout
- 9.4.2.2. CRISPR Knockin
- 9.4.2.3. Random Insertions
- 9.4.2.4. Large, Targeted Insertions
- 9.4.2.5. ES Cell Modification (homologous recombination)
- 9.4.2.6. Others
- 9.4.3. Academic & Research Facilities
- 9.4.3.1. CRISPR Knockout
- 9.4.3.2. CRISPR Knockin
- 9.4.3.3. Random Insertions
- 9.4.3.4. Large, Targeted Insertions
- 9.4.3.5. ES Cell Modification (homologous recombination)
- 9.4.3.6. Others
- 9.4.4. Contract Research & Manufacturing Organizations
- 9.4.4.1. CRISPR Knockout
- 9.4.4.2. CRISPR Knockin
- 9.4.4.3. Random Insertions
- 9.4.4.4. Large, Targeted Insertions
- 9.4.4.5. ES Cell Modification (homologous recombination)
- 9.4.4.6. Others
- 9.5. Market Value Forecast, by Country, 2017–2031
- 9.5.1. U.S.
- 9.5.2. Canada
- 9.6. Market Attractiveness Analysis
- 9.6.1. By Technology
- 9.6.2. By End-user
- 9.6.3. By End-user by Technology
- 9.6.4. By Country
- 10. Europe Mice Model Generation Market Analysis and Forecast
- 10.1. Introduction
- 10.1.1. Key Findings
- 10.2. Market Value Forecast, by Technology, 2017–2031
- 10.2.1. CRISPR Knockout
- 10.2.2. CRISPR Knockin
- 10.2.3. Random Insertions
- 10.2.4. Large, Targeted Insertions
- 10.2.5. ES Cell Modification (homologous recombination)
- 10.2.6. Others
- 10.3. Market Value Forecast, by End-user, 2017–2031
- 10.3.1. Pharmaceutical Companies
- 10.3.2. Biotechnology Companies
- 10.3.3. Academic & Research Facilities
- 10.3.4. Contract Research & Manufacturing Organizations
- 10.4. Market Value Forecast, by End-user by Technology, 2017–2031
- 10.4.1. Pharmaceutical Companies
- 10.4.1.1. CRISPR Knockout
- 10.4.1.2. CRISPR Knockin
- 10.4.1.3. Random Insertions
- 10.4.1.4. Large, Targeted Insertions
- 10.4.1.5. ES Cell Modification (homologous recombination)
- 10.4.1.6. Others
- 10.4.2. Biotechnology Companies
- 10.4.2.1. CRISPR Knockout
- 10.4.2.2. CRISPR Knockin
- 10.4.2.3. Random Insertions
- 10.4.2.4. Large, Targeted Insertions
- 10.4.2.5. ES Cell Modification (homologous recombination)
- 10.4.2.6. Others
- 10.4.3. Academic & Research Facilities
- 10.4.3.1. CRISPR Knockout
- 10.4.3.2. CRISPR Knockin
- 10.4.3.3. Random Insertions
- 10.4.3.4. Large, Targeted Insertions
- 10.4.3.5. ES Cell Modification (homologous recombination)
- 10.4.3.6. Others
- 10.4.4. Contract Research & Manufacturing Organizations
- 10.4.4.1. CRISPR Knockout
- 10.4.4.2. CRISPR Knockin
- 10.4.4.3. Random Insertions
- 10.4.4.4. Large, Targeted Insertions
- 10.4.4.5. ES Cell Modification (homologous recombination)
- 10.4.4.6. Others
- 10.5. Market Value Forecast, by Country/Sub-region, 2017–2031
- 10.5.1. Germany
- 10.5.2. U.K.
- 10.5.3. France
- 10.5.4. Spain
- 10.5.5. Italy
- 10.5.6. Rest of Europe
- 10.6. Market Attractiveness Analysis
- 10.6.1. By Technology
- 10.6.2. By End-user
- 10.6.3. By End-user by Technology
- 10.6.4. By Country/Sub-region
- 11. Asia Pacific Mice Model Generation Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Market Value Forecast, by Technology, 2017–2031
- 11.2.1. CRISPR Knockout
- 11.2.2. CRISPR Knockin
- 11.2.3. Random Insertions
- 11.2.4. Large, Targeted Insertions
- 11.2.5. ES Cell Modification (homologous recombination)
- 11.2.6. Others
- 11.3. Market Value Forecast, by End-user, 2017–2031
- 11.3.1. Pharmaceutical Companies
- 11.3.2. Biotechnology Companies
- 11.3.3. Academic & Research Facilities
- 11.3.4. Contract Research & Manufacturing Organizations
- 11.4. Market Value Forecast, by End-user by Technology, 2017–2031
- 11.4.1. Pharmaceutical Companies
- 11.4.1.1. CRISPR Knockout
- 11.4.1.2. CRISPR Knockin
- 11.4.1.3. Random Insertions
- 11.4.1.4. Large, Targeted Insertions
- 11.4.1.5. ES Cell Modification (homologous recombination)
- 11.4.1.6. Others
- 11.4.2. Biotechnology Companies
- 11.4.2.1. CRISPR Knockout
- 11.4.2.2. CRISPR Knockin
- 11.4.2.3. Random Insertions
- 11.4.2.4. Large, Targeted Insertions
- 11.4.2.5. ES Cell Modification (homologous recombination)
- 11.4.2.6. Others
- 11.4.3. Academic & Research Facilities
- 11.4.3.1. CRISPR Knockout
- 11.4.3.2. CRISPR Knockin
- 11.4.3.3. Random Insertions
- 11.4.3.4. Large, Targeted Insertions
- 11.4.3.5. ES Cell Modification (homologous recombination)
- 11.4.3.6. Others
- 11.4.4. Contract Research & Manufacturing Organizations
- 11.4.4.1. CRISPR Knockout
- 11.4.4.2. CRISPR Knockin
- 11.4.4.3. Random Insertions
- 11.4.4.4. Large, Targeted Insertions
- 11.4.4.5. ES Cell Modification (homologous recombination)
- 11.4.4.6. Others
- 11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
- 11.5.1. China
- 11.5.2. Japan
- 11.5.3. India
- 11.5.4. Australia & New Zealand
- 11.5.5. Rest of Asia Pacific
- 11.6. Market Attractiveness Analysis
- 11.6.1. By Technology
- 11.6.2. By End-user
- 11.6.3. By End-user by Technology
- 11.6.4. By Country/Sub-region
- 12. Latin America Mice Model Generation Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast, by Technology, 2017–2031
- 12.2.1. CRISPR Knockout
- 12.2.2. CRISPR Knockin
- 12.2.3. Random Insertions
- 12.2.4. Large, Targeted Insertions
- 12.2.5. ES Cell Modification (homologous recombination)
- 12.2.6. Others
- 12.3. Market Value Forecast, by End-user, 2017–2031
- 12.3.1. Pharmaceutical Companies
- 12.3.2. Biotechnology Companies
- 12.3.3. Academic & Research Facilities
- 12.3.4. Contract Research & Manufacturing Organizations
- 12.4. Market Value Forecast, by End-user by Technology, 2017–2031
- 12.4.1. Pharmaceutical Companies
- 12.4.1.1. CRISPR Knockout
- 12.4.1.2. CRISPR Knockin
- 12.4.1.3. Random Insertions
- 12.4.1.4. Large, Targeted Insertions
- 12.4.1.5. ES Cell Modification (homologous recombination)
- 12.4.1.6. Others
- 12.4.2. Biotechnology Companies
- 12.4.2.1. CRISPR Knockout
- 12.4.2.2. CRISPR Knockin
- 12.4.2.3. Random Insertions
- 12.4.2.4. Large, Targeted Insertions
- 12.4.2.5. ES Cell Modification (homologous recombination)
- 12.4.2.6. Others
- 12.4.3. Academic & Research Facilities
- 12.4.3.1. CRISPR Knockout
- 12.4.3.2. CRISPR Knockin
- 12.4.3.3. Random Insertions
- 12.4.3.4. Large, Targeted Insertions
- 12.4.3.5. ES Cell Modification (homologous recombination)
- 12.4.3.6. Others
- 12.4.4. Contract Research & Manufacturing Organizations
- 12.4.4.1. CRISPR Knockout
- 12.4.4.2. CRISPR Knockin
- 12.4.4.3. Random Insertions
- 12.4.4.4. Large, Targeted Insertions
- 12.4.4.5. ES Cell Modification (homologous recombination)
- 12.4.4.6. Others
- 12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
- 12.5.1. Brazil
- 12.5.2. Mexico
- 12.5.3. Rest of Latin America
- 12.6. Market Attractiveness Analysis
- 12.6.1. By Technology
- 12.6.2. By End-user
- 12.6.3. By End-user by Technology
- 12.6.4. By Country/Sub-region
- 13. Middle East & Africa Mice Model Generation Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast, by Technology, 2017–2031
- 13.2.1. CRISPR Knockout
- 13.2.2. CRISPR Knockin
- 13.2.3. Random Insertions
- 13.2.4. Large, Targeted Insertions
- 13.2.5. ES Cell Modification (homologous recombination)
- 13.2.6. Others
- 13.3. Market Value Forecast, by End-user, 2017–2031
- 13.3.1. Pharmaceutical Companies
- 13.3.2. Biotechnology Companies
- 13.3.3. Academic & Research Facilities
- 13.3.4. Contract Research & Manufacturing Organizations
- 13.4. Market Value Forecast, by End-user by Technology, 2017–2031
- 13.4.1. Pharmaceutical Companies
- 13.4.1.1. CRISPR Knockout
- 13.4.1.2. CRISPR Knockin
- 13.4.1.3. Random Insertions
- 13.4.1.4. Large, Targeted Insertions
- 13.4.1.5. ES Cell Modification (homologous recombination)
- 13.4.1.6. Others
- 13.4.2. Biotechnology Companies
- 13.4.2.1. CRISPR Knockout
- 13.4.2.2. CRISPR Knockin
- 13.4.2.3. Random Insertions
- 13.4.2.4. Large, Targeted Insertions
- 13.4.2.5. ES Cell Modification (homologous recombination)
- 13.4.2.6. Others
- 13.4.3. Academic & Research Facilities
- 13.4.3.1. CRISPR Knockout
- 13.4.3.2. CRISPR Knockin
- 13.4.3.3. Random Insertions
- 13.4.3.4. Large, Targeted Insertions
- 13.4.3.5. ES Cell Modification (homologous recombination)
- 13.4.3.6. Others
- 13.4.4. Contract Research & Manufacturing Organizations
- 13.4.4.1. CRISPR Knockout
- 13.4.4.2. CRISPR Knockin
- 13.4.4.3. Random Insertions
- 13.4.4.4. Large, Targeted Insertions
- 13.4.4.5. ES Cell Modification (homologous recombination)
- 13.4.4.6. Others
- 13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
- 13.5.1. GCC Countries
- 13.5.2. South Africa
- 13.5.3. Rest of Middle East & Africa
- 13.6. Market Attractiveness Analysis
- 13.6.1. By Technology
- 13.6.2. By End-user
- 13.6.3. By End-user by Technology
- 13.6.4. By Country/Sub-region
- 14. Competition Landscape
- 14.1. Market Player - Competition Matrix (by tier and size of companies)
- 14.2. Market Share Analysis, by Company, 2021
- 14.2.1. Global
- 14.2.2. North America
- 14.2.3. Europe
- 14.2.4. By Asia Pacific
- 14.2.5. By Latin America
- 14.2.6. By Middle East & Africa
- 14.3. Company Profiles
- 14.3.1. Biocytogen
- 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.1.2. Product Portfolio
- 14.3.1.3. SWOT Analysis
- 14.3.1.4. Strategic Overview
- 14.3.2. Charles River Laboratories
- 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.2.2. Product Portfolio
- 14.3.2.3. SWOT Analysis
- 14.3.2.4. Strategic Overview
- 14.3.3. Cyagen Biosciences
- 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.3.2. Product Portfolio
- 14.3.3.3. SWOT Analysis
- 14.3.3.4. Strategic Overview
- 14.3.4. Gempharmatech
- 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.4.2. Product Portfolio
- 14.3.4.3. SWOT Analysis
- 14.3.4.4. Strategic Overview
- 14.3.5. genOway
- 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.5.2. Product Portfolio
- 14.3.5.3. SWOT Analysis
- 14.3.5.4. Strategic Overview
- 14.3.6. ingenious targeting laboratory
- 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.6.2. Product Portfolio
- 14.3.6.3. SWOT Analysis
- 14.3.6.4. Strategic Overview
- 14.3.7. Merck KGaA
- 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.7.2. Product Portfolio
- 14.3.7.3. SWOT Analysis
- 14.3.7.4. Strategic Overview
- 14.3.8. Ozgene Pty Ltd.
- 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.8.2. Product Portfolio
- 14.3.8.3. SWOT Analysis
- 14.3.8.4. Strategic Overview
- 14.3.9. Taconic Biosciences, Inc.
- 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.9.2. Product Portfolio
- 14.3.9.3. SWOT Analysis
- 14.3.9.4. Strategic Overview
- 14.3.10. PolyGene AG
- 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.10.2. Product Portfolio
- 14.3.10.3. SWOT Analysis
- 14.3.10.4. Strategic Overview
- 14.3.11. The Jackson Laboratory
- 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.11.2. Product Portfolio
- 14.3.11.3. SWOT Analysis
- 14.3.11.4. Strategic Overview
- 14.3.12. Yale School of Medicine
- 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.12.2. Product Portfolio
- 14.3.12.3. SWOT Analysis
- 14.3.12.4. Strategic Overview
- 14.3.13. University of North Carolina
- 14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.13.2. Product Portfolio
- 14.3.13.3. SWOT Analysis
- 14.3.13.4. Strategic Overview
- 14.3.14. University of Nebraska Medical Center
- 14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.14.2. Product Portfolio
- 14.3.14.3. SWOT Analysis
- 14.3.14.4. Strategic Overview
- 14.3.15. Monash University
- 14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.15.2. Product Portfolio
- 14.3.15.3. SWOT Analysis
- 14.3.15.4. Strategic Overview
- 14.3.16. UMass Chan Medical School
- 14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.16.2. Product Portfolio
- 14.3.16.3. SWOT Analysis
- 14.3.16.4. Strategic Overview
- 14.3.17. University of Bonn
- 14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.17.2. Product Portfolio
- 14.3.17.3. SWOT Analysis
- 14.3.17.4. Strategic Overview
- 14.3.18. Columbia University
- 14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.18.2. Product Portfolio
- 14.3.18.3. SWOT Analysis
- 14.3.18.4. Strategic Overview
- 14.3.19. The University of Arizona
- 14.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.19.2. Product Portfolio
- 14.3.19.3. SWOT Analysis
- 14.3.19.4. Strategic Overview
- 14.3.20. Hadassah BrainLabs
- 14.3.20.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.20.2. Product Portfolio
- 14.3.20.3. SWOT Analysis
- 14.3.20.4. Strategic Overview
- 14.3.21. The Weizmann Institute of Science
- 14.3.21.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.21.2. Product Portfolio
- 14.3.21.3. SWOT Analysis
- 14.3.21.4. Strategic Overview
- 14.3.22. The Hebrew University of Jerusalem
- 14.3.22.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.22.2. Product Portfolio
- 14.3.22.3. SWOT Analysis
- 14.3.22.4. Strategic Overview
- 14.3.23. The Technion – Israel Institute of Technology
- 14.3.23.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.23.2. Product Portfolio
- 14.3.23.3. SWOT Analysis
- 14.3.23.4. Strategic Overview
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook